Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05972720 Recruiting - Cancer Clinical Trials

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

FIRCE-1
Start date: August 1, 2023
Phase: Phase 2
Study type: Interventional

This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).

NCT ID: NCT05972577 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.

NCT ID: NCT05969821 Not yet recruiting - Lymphoma Clinical Trials

Clonal Hematopoiesis of Immunological Significance

CHIS
Start date: September 2023
Phase:
Study type: Observational [Patient Registry]

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

NCT ID: NCT05968963 Recruiting - Clinical trials for Myelodysplastic Syndromes

Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation

Start date: November 28, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to pilot test an Electronic Health Mindfulness-based Music Therapy Intervention (eMBMT) intervention to improve health-related quality of life (HRQoL) and reduce symptom burden of patients undergoing allogeneic stem cell transplantation (allo-SCT).

NCT ID: NCT05968001 Not yet recruiting - Clinical trials for Lymphomas Non-Hodgkin's B-Cell

Obinutuzumab in Chinese Real-world Patients With iNHL

Start date: July 20, 2023
Phase:
Study type: Observational

This study aims to assess the clinical efficacy and safety of obinutuzumab in Chinese patients with indolent non-Hodgkin B-cell Lymphoma (predominantly Follicular lymphoma and Marginal zone lymphoma) in a real-world setting.

NCT ID: NCT05967975 Not yet recruiting - Lymphoma Clinical Trials

Elastography and Treatment of Lymphoma

Start date: August 2023
Phase:
Study type: Observational

To determine accuracy of elastography in assessment of superficial lymph nodes response to treatment in cases of lymphoma.

NCT ID: NCT05967416 Recruiting - Clinical trials for Refractory Non-Hodgkin Lymphoma

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Start date: December 2023
Phase: Phase 1
Study type: Interventional

The goal of this study is to test SIRPant-M, an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

NCT ID: NCT05966233 Withdrawn - Clinical trials for Diffuse Large B-cell Lymphoma Recurrent

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

FIL_POLARDHAP
Start date: January 2024
Phase: Phase 2
Study type: Interventional

Prospective, multicenter, open label, phase II randomized clinical trial in DLBCL patients relapsed or refractory to first line R-chemo, aged 18-70 years and candidate to autologous transplant. Patients will be randomized 1:1 to received 4 cycles of R-DHAP or R-DHAP plus Polatuzumab Vedotin as induction treatment plus autologous transplant.

NCT ID: NCT05965505 Recruiting - Clinical trials for Relapsed or Refractory Non-Hodgkin's Lymphoma

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Start date: August 11, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, multicenter, phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in adult subjects with Relapsed/Refractory Non-Hodgkin Lymphomas.

NCT ID: NCT05963347 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

Go-CHOP as the Frontline Therapy for PTCL

Start date: August 3, 2023
Phase: Phase 2
Study type: Interventional

This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).